In PD, a special clinical interest is focused on β-ARs signaling, since PD animal models and human patients show a link between promoting β-ARs signaling and a reduction of PD risk and pathology, whereas blocking β-ARs is associated with increased PD risk [15–18]. This evidence concerns the gene CTBP1 and Parkinson disease.